Topokine Therapeutics Report issue

For profit Phase 2 Phase 3
Founded: Boston MA United States (2010)
Status: Acquired by Allergan PLC (2015) (2016) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2012
NCT01723241
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Topokine Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

xoph5 (4 trials)

Drugs in Phase 2 Trials (1)

tat4 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lipodystrophy (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 2